Skip to main navigation Skip to search Skip to main content

Reduced Serological Response to COVID-19 Booster Vaccine is Associated with Reduced B Cell Memory in Patients With Inflammatory Bowel Disease; VARIATION [VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON]

  • Jayne Doherty
  • , Neil O’Morain
  • , Roisin Stack
  • , Miriam Tosetto
  • , Rosanna Inzitiari
  • , Sophie O’Reilly
  • , Lili Gu
  • , Juliette Sheridan
  • , Garret Cullen
  • , Edel Mc Dermott
  • , Maire Buckley
  • , Gareth Horgan
  • , Hugh Mulcahy
  • , Margaret Walshe
  • , Elizabeth J. Ryan
  • , Virginie Gautier
  • , John Prostko
  • , Edwin Frias
  • , David Daghfal
  • , Peter Doran
  • Colm O’Morain, Glen A. Doherty
  • University College Dublin
  • INITIative IBD Research Network
  • St. Michael's Hospital
  • St Columcille's Hospital
  • Abbott Diagnostics
  • Trinity College Dublin

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Aims: Patients with inflammatory bowel disease [IBD] have an attenuated response to initial COVID-19 vaccination. We sought to characterize the impact of IBD and its treatment on responses after the third vaccine against SARS-CoV-2. Methods: This was a prospective multicentre observational study of patients with IBD [n = 202] and healthy controls [HC, n = 92]. Serological response to vaccination was assessed by quantification of anti-spike protein [SP] immunoglobulin [Ig]G levels [anti-SPIgG] and in vitro neutralization of binding to angiotensin-converting enzyme 2 [ACE2]. Peripheral blood B-cell phenotype populations were assessed by flow cytometry. SARS-CoV-2 antigen-specific B-cell responses were assessed in ex vivo culture. Results: Median anti-SP IgG post-third vaccination in our IBD cohort was significantly lower than HCs [7862 vs 19 622 AU/mL, p < 0.001] as was ACE2 binding inhibition [p < 0.001]. IBD patients previously infected with COVID-19 [30%] had similar quantitative antibody response as HCs previously infected with COVID-19 [p = 0.12]. Lowest anti-SP IgG titres and neutralization were seen in IBD patients on anti-tumour necrosis factor [anti-TNF] agents, without prior COVID-19 infection, but all IBD patients show an attenuated vaccine response compared to HCs. Patients with IBD have reduced memory B-cell populations and attenuated B-cell responses to SARS-CoV-2 antigens if not previously infected with COVID-19 [p = 0.01]. Higher anti-TNF drug levels and zinc levels <65 ng/ml were associated with significantly lower serological responses. Conclusions: Patients with IBD have an attenuated response to three doses of SARS-CoV-2 vaccine. Physicians should consider patients with higher anti-TNF drug levels and/or zinc deficiency as potentially at higher risk of attenuated response to vaccination.

Original languageEnglish
Pages (from-to)1445-1456
Number of pages12
JournalJournal of Crohn's and Colitis
Volume17
Issue number9
DOIs
Publication statusPublished - 1 Sep 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • COVID-19 vaccination
  • Inflammatory bowel disease
  • immune response
  • memory B-cell response

Fingerprint

Dive into the research topics of 'Reduced Serological Response to COVID-19 Booster Vaccine is Associated with Reduced B Cell Memory in Patients With Inflammatory Bowel Disease; VARIATION [VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON]'. Together they form a unique fingerprint.

Cite this